{"DataElement":{"publicId":"6738977","version":"1","preferredName":"Disease Response International Myeloma Working Group Standard Response Criteria Category","preferredDefinition":"Categorization of response to treatment based on criteria created by the International Myeloma Working Group (IMWG).","longName":"RESP_IMWG_STD_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6738971","version":"1","preferredName":"Disease Response International Myeloma Working Group Standard Response Criteria","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment.","longName":"2607696v1.0:6738969v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2607696","version":"1","preferredName":"Response","preferredDefinition":"In medicine, an improvement related to treatment.","longName":"C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF31F79-4CA1-08D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-05","endDate":null,"createdBy":"UMLLOADER_CTOM","dateCreated":"2007-03-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6738969","version":"1","preferredName":"International Myeloma Working Group Standard Response Criteria","preferredDefinition":"Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment.","longName":"C159804","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Myeloma Working Group Standard Response Criteria","conceptCode":"C159804","definition":"Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C51A0B-2A9B-5AB2-E053-F662850A5CFA","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C51A0B-2AAC-5AB2-E053-F662850A5CFA","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6738951","version":"1","preferredName":"Standard IMWG Category","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics.","longName":"IMWG_STD_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Progressive disease (PD)","valueDescription":"IMWG Progressive Disease","ValueMeaning":{"publicId":"6738952","version":"1","preferredName":"IMWG Progressive Disease","longName":"6738952","preferredDefinition":"Any one or more of the following criteria: increase of 25 percent from lowest confirmed response value in one or more of the following criteria: serum M-protein (absolute increase must be at least 0.5 g/dL); serum M-protein increase at least 1 g/dL, if the lowest M component was at least 5 g/dL; urine M-protein (absolute increase must be at least 200 mg/24 h); in patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain levels (absolute increase must be greater than 10 mg/dL); in patients without measurable serum and urine M-protein levels and without measurable involved free light chain levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be at least 10 percent); appearance of a new lesion(s), at least 50 percent increase from nadir in sum of products of diameters of greater than 1 lesion, or at least 50 percent increase in the longest diameter of a previous lesion greater than 1 cm in short axis; at least 50 percent increase in circulating plasma cells (minimum of 200 cells per uL) if this is the only measure of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Progressive Disease","conceptCode":"C159811","definition":"Any one or more of the following criteria: increase of 25 percent from lowest confirmed response value in one or more of the following criteria: serum M-protein (absolute increase must be at least 0.5 g/dL); serum M-protein increase at least 1 g/dL, if the lowest M component was at least 5 g/dL; urine M-protein (absolute increase must be at least 200 mg/24 h); in patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain levels (absolute increase must be greater than 10 mg/dL); in patients without measurable serum and urine M-protein levels and without measurable involved free light chain levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be at least 10 percent); appearance of a new lesion(s), at least 50 percent increase from nadir in sum of products of diameters of greater than 1 lesion, or at least 50 percent increase in the longest diameter of a previous lesion greater than 1 cm in short axis; at least 50 percent increase in circulating plasma cells (minimum of 200 cells per uL) if this is the only measure of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2AA2-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2ABB-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Stable disease (SD)","valueDescription":"IMWG Stable Disease","ValueMeaning":{"publicId":"6738953","version":"1","preferredName":"IMWG Stable Disease","longName":"6738953","preferredDefinition":"Not recommended for use as an indicator of response. Stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Stable Disease","conceptCode":"C159810","definition":"Not recommended for use as an indicator of response. Stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2AC7-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2AE0-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Minimal response (MR)","valueDescription":"IMWG Minimal Response","ValueMeaning":{"publicId":"6738954","version":"1","preferredName":"IMWG Minimal Response","longName":"6738954","preferredDefinition":"At least 25 percent but less than 50 percent reduction of serum M-protein and reduction in 24-hour urine M-protein by 50-89 percent. In addition to the above listed criteria, if present at baseline, at least a 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Minimal Response","conceptCode":"C159809","definition":"At least 25 percent but less than 50 percent reduction of serum M-protein and reduction in 24-hour urine M-protein by 50-89 percent. In addition to the above listed criteria, if present at baseline, at least a 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2AEC-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2B05-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Partial response (PR)","valueDescription":"IMWG Partial Response","ValueMeaning":{"publicId":"6738955","version":"1","preferredName":"IMWG Partial Response","longName":"6738955","preferredDefinition":"At least 50 percent reduction of serum M-protein plus reduction in 24 hour urinary M-protein by at least 90 percent or to less than 200 mg per 24 hour. If the serum and urine M-protein are unmeasurable, at least a 50 percent decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, at least a 50 percent reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was at least 30 percent. In addition to these criteria, if present at baseline, at least 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Partial Response","conceptCode":"C159808","definition":"At least 50 percent reduction of serum M-protein plus reduction in 24 hour urinary M-protein by at least 90 percent or to less than 200 mg per 24 hour. If the serum and urine M-protein are unmeasurable, at least a 50 percent decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, at least a 50 percent reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was at least 30 percent. In addition to these criteria, if present at baseline, at least 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2B11-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2B2A-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Very good partial response (VGPR)","valueDescription":"IMWG Very Good Partial Response","ValueMeaning":{"publicId":"6738956","version":"1","preferredName":"IMWG Very Good Partial Response","longName":"6738956","preferredDefinition":"Serum and urine M-protein detectable by immunofixation but not on electrophoresis or at least 90 percent reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Very Good Partial Response","conceptCode":"C159807","definition":"Serum and urine M-protein detectable by immunofixation but not on electrophoresis or at least 90 percent reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2B36-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2B4F-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Complete response (CR)","valueDescription":"IMWG Complete Response","ValueMeaning":{"publicId":"6738957","version":"1","preferredName":"IMWG Complete Response","longName":"6738957","preferredDefinition":"Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than 5 percent plasma cells in bone marrow aspirates.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Complete Response","conceptCode":"C159806","definition":"Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than 5 percent plasma cells in bone marrow aspirates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2B5B-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2B74-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Stringent complete response (sCR)","valueDescription":"IMWG Stringent Complete Response","ValueMeaning":{"publicId":"6738958","version":"1","preferredName":"IMWG Stringent Complete Response","longName":"6738958","preferredDefinition":"Complete response, plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry (kappa/lambda ratio less than or equal to 4:1 or greater than or equal to 1:2 for kappa and lambda patients, respectively, after counting at least 100 plasma cells).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Stringent Complete Response","conceptCode":"C159805","definition":"Complete response, plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry (kappa/lambda ratio less than or equal to 4:1 or greater than or equal to 1:2 for kappa and lambda patients, respectively, after counting at least 100 plasma cells).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2B80-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C4DBB9-2B99-3C3C-E053-F662850AAFD4","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBB9-2A8A-3C3C-E053-F662850AAFD4","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Standard IMWG response criter","type":"Preferred Question Text","description":"Standard IMWG response criteria","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C52E17-A446-490C-E053-F662850A01E6","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}